Free Trial
NASDAQ:ANGN

Angion Biomedica (ANGN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$1.00
$10.00
52-Week Range
N/A
Volume
224,800 shs
Average Volume
86,718 shs
Market Capitalization
$30.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ANGN stock logo

About Angion Biomedica Stock (NASDAQ:ANGN)

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.

ANGN Stock News Headlines

8-K: Angion Biomedica Corp.
Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View
Angion Biomedica Corp. (ANGN)
See More Headlines
Receive ANGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
5/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ANGN
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-38,810,000.00
Pretax Margin
-4,456.97%

Debt

Sales & Book Value

Annual Sales
$2.30 million
Book Value
$1.32 per share

Miscellaneous

Free Float
24,182,000
Market Cap
$30.11 million
Optionable
Not Optionable
Beta
0.60
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives


ANGN Stock Analysis - Frequently Asked Questions

How were Angion Biomedica's earnings last quarter?

Angion Biomedica Corp. (NASDAQ:ANGN) issued its quarterly earnings data on Friday, November, 12th. The company reported ($5.30) EPS for the quarter, topping analysts' consensus estimates of ($7.30) by $2.00. The company had revenue of $1.46 million for the quarter, compared to analyst estimates of $1.08 million.

When did Angion Biomedica's stock split?

Angion Biomedica shares reverse split before market open on Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Angion Biomedica IPO?

Angion Biomedica (ANGN) raised $75 million in an IPO on Friday, February 5th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Stifel served as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

This page (NASDAQ:ANGN) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners